The research, published in EMBO Molecular Medicine, analyzed blood samples from 779 participants over 17 years, demonstrating that the misfolding biomarker achieved an area under the curve (AUC) of 0.79, indicating strong predictive power in cognitively normal individuals. In contrast, P-tau 217 showed moderate predictive ability (AUC = 0.67) in the preclinical stage but excelled once the disease manifested clinically. The findings suggest that incorporating this biomarker into screening strategies could enhance early identification and intervention, potentially improving outcomes for at-risk populations.